Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma

• Published in: Journal of Egyptian National Cancer Institute 2024-03, Vol.36 (1), p.7-11
• Main Authors: Ray, Suman Kumar, Mukherjee, Sukhes
• Format: Article
• Language: English
• Subjects: Antigens; Autophagy; B cells; Cancer; Carcinoma; Cell adhesion & migration; Chemokines; Cloning; Colorectal cancer; Colorectal carcinoma; Concomitant immunity; Cytokines; Development and progression; Dissemination; Endothelium; Extracellular vesicles; Hypotheses; Immune landscape; Immunotherapy; Metastasis; Mortality; Mutation; Proteins; Stem cells; Systemic priming; Tumors
• ISSN: 1110-0362; 2589-0409
• DOI: 10.1186/s43046-024-00211-9

The progression of metastasis, a complex systemic disease, is facilitated by interactions between tumor cells and their isolated microenvironments. Over the past few decades, researchers have investigated the metastatic spread of cancer extensively, identifying multiple stages in the process, such as intravasation, extravasation, tumor latency, and the development of micrometastasis and macrometastasis. The premetastatic niche is established in target organs by the accumulation of aberrant immune cells and extracellular matrix proteins. The "seed and soil" idea, which has become widely known and accepted, is being used to this day to guide cancer studies. Changes in the local and systemic immune systems have a major impact on whether an infection spreads or not. The belief that the immune response may play a role in slowing tumor growth and may be beneficial against the metastatic disease underpins the responsiveness shown in the immunological landscape of metastasis. Various hypotheses on the phylogenesis of metastases have been proposed in the past. The primary tumor's secreting factors shape the intratumoral microenvironment and the immune landscape, allowing this progress to be made. Therefore, it is evident that among disseminated tumor cells, there are distinct phenotypes that either carry budding for metastasis or have the ability to obtain this potential or in systemic priming through contact with substantial metastatic niches that have implications for medicinal chemistry. Concurrent immunity signals that the main tumor induces an immune response that may not be strong enough to eradicate the tumor. Immunotherapy's success with some cancer patients shows that it is possible to effectively destroy even advanced-stage tumors by modifying the microenvironment and tumor-immune cell interactions. This review focuses on the metastasome in colorectal carcinoma and the therapeutic implications of site-specific metastasis, systemic priming, tumor spread, and the relationship between the immune system and metastasis.